Editorials

Methotrexate Therapy for Psoriatic Arthritis: Reappraisal of an Old Remedy
L.A. Saketkoo, R. Cuchacovich, L.R. Espinoza ........................................... 369

Lessons from Magnetic Resonance Imaging Studies in Rheumatoid Arthritis M. Quinn .................................................. 372

Infections, Drugs, and Rheumatoid Arthritis. What Have We Learned? J.S. Coblyn .......................................................... 375

Diffuse Idiopathic Skeletal Hyperostosis: Time for a Change R. Mader .......................................................... 377

Articles

Anemia in Early RA Is Associated with IL-6-Mediated Bone Marrow Suppression, But Has No Effect on Disease Course or Mortality
C. Nikolaisen, Y. Figenschau, J.C. Nossent .................................................. 380

The Risk of Hospitalized Infection in Patients with RA

Etanercept Reduces Synovitis as Measured by MRI in Patients with Active RA After Only 6 Weeks
M.P. Lisbona, J. Maymo, J. Perich, M. Almirall, C. Pérez-García, J. Carbonell .................................................. 394

Endothelial Dysfunction and Atherosclerosis in RA: A Multimetric Analysis Using Imaging Techniques and Laboratory Markers of Inflammation and Autoimmunity
G. Kerekes, Z. Szekanecz, H. Dér, et al .................................................. 398

Osteoclast Inhibitory Effects of Vitamin K, Alone or in Combination with Etidronate or Risedronate in Patients with RA: 2-Year Results
M. Morishita, M. Nagashima, K. Wauke, H. Takahashi, K. Takenouchi .................................................. 407

Easy and Accurate Diagnosis of RA Using Anti-CCP2 Antibody, Swollen Joint Count, and CRP/RF
T. Yamane, A. Hashiramoto, Y. Tanaka, et al .................................................. 414

Short-Term Course of Chronic Hepatitis B and C Under Treatment with Etanercept Associated with Different DMARD without Antiviral Prophylaxis
D.U. Cansu, T. Kalejoğlu, C. Korkmaz .................................................. 421

IgM-RF, Anti-CCP, and Anti-Citrullinated Human Fibrinogen Antibodies Decrease During Treatment with the TNF Blocker Infliximab in Patients with RA
M. Vis, W.H. Bos, G. Wolbink, et al .................................................. 425

Clinical and Immunologic Manifestations of MCTD in a Miami Population Compared to a Midwestern US Caucasian Population
M.E. Maldonado, M. Perez, J. Pignac-Kobinger, et al ................................................. 429

DM and PM Associated with Malignancy: A 21-year Retrospective Study
C. András, A. Ponyi, T. Constantín, et al .................................................. 438

Epidemiology of Sporadic Inclusion Body Myositis and PM in Olmsted County, Minnesota
F.C. Wilson, S.R. Ytterberg, J.L. St. Sauver, A.M. Reed ................................................. 445

Relapses in Patients with ANCA-Associated Vasculitis: Likely to Begin with the Same Organ as Initial Onset
M. Chen, P. Yu, M-H. Zhao .................................................. 448

Anti-p53 Autoantibody in SSC: Association with Limited Cutaneous SSC
T. Hara, F. Ogawa, E. Muroi, et al .................................................. 451

Assessment of Pulmonary Arterial Hypertension in Patients with SSC: Comparison of Noninvasive Tests with Results of Right-Heart Catheterization
V.M. Hsu, A.E. Moreyra, A.C. Wilson, et al .................................................. 458

Does Incorporation of AIDS and Devices Make a Difference in the Score of the HAQ-Disability Index?
Analysis from a Scleroderma Clinical Trial
D. Khanna, P.J. Clements, A.E. Postlethwaite, D.E. Furst, for the Scleroderma Collagen Type 1 Study Group .................................................. 466

Reappraisal of the Effectiveness of MTX in PsA: Results from a Longitudinal Observational Cohort
V. Chandran, C.T. Schentag, D.D. Gladman .................................................. 469

Treatment of PsA and RA with Disease Modifying Drugs — Comparison of Drugs and Adverse Reactions
P.S. Helliwell, W.J. Taylor for the CASPAR Study Group ................................................. 472

Do We Really Need to Evaluate Entire Cervical Spines for Squaring Score in Modified Stoke AS Spinal Score?
T-J. Kim, H-S. Kim, K-B. Joo, S. Kim, T-H. Kim .................................................. 477

A Comparison of Self-reported Joint Symptoms Following Infection with Different Enteric Pathogens: Effect of HLA-B27
P. Schiellerup, K.A. Krogfelt, H. Locht .................................................. 480

Efficacy and Tolerability of IV Ibandronate Injections in Postmenopausal Osteoporosis: 2-Year Results from the DIVA Study J.A. Eisman, R. Civitelli, S. Adami, et al .................................................. 488

Gout in Ambulatory Care Settings in the US
E. Krishnan, D. Lienesch, C.K. Kwoh .................................................. 498

Contents continued opposite inside back cover . . .